Strong immunohistochemical expression of fibroblast growth factor receptor 3, superficial staining pattern of cytokeratin 20, and low proliferative activity define those papillary urothelial neoplasms of low malignant potential that do not recur
- PMID: 18072261
- DOI: 10.1002/cncr.23212
Strong immunohistochemical expression of fibroblast growth factor receptor 3, superficial staining pattern of cytokeratin 20, and low proliferative activity define those papillary urothelial neoplasms of low malignant potential that do not recur
Abstract
Background: Papillary urothelial neoplasm of low malignant potential (PUNLMP) is a clinically significant lesion because recurrence occurs in approximately 35% of patients. To date, it is not possible to identify those cases that will recur based on conventional histopathologic assessment. The objective of the current study was to evaluate immunohistochemically tissue expression of fibroblast growth factor receptor 3 (FGFR3), cytokeratin 20 (CK20), and MIB-1 in nonrecurrent and recurrent PUNLMP.
Methods: FGFR3, CK20, and MIB-1 were investigated by immunohistochemistry (IHC) in 80 PUNLMP cases (41 nonrecurrent and 39 recurrent), in 4 cases of normal urothelium (NU), and in 5 cases of muscle invasive pT2 urothelial carcinoma (UC). Statistics included discriminant analysis.
Results: NU demonstrated a weak to moderate FRFG3 staining intensity, a superficial pattern of CK20 staining, and low proliferative activity. UC was found to have FGFR3 staining similar to NU, an abnormal CK20 expression, and high proliferative activity. The nonrecurrent PUNLMP group demonstrated strong FGFR3 intensity in 80.5% of the cases (vs 56.4% of the recurrent cases), a superficial CK20 staining pattern in 53.7% of the cases (vs 28.2% of the recurrent cases), and a percentage of MIB-1-positive nuclei below the median value of all the PUNLMP cases in 61% of the cases (35.9% in the recurrent cases). The differences were statistically significant. Discriminant analysis based on these 3 features demonstrated that 67.5% of cross-validated grouped PUNLMP cases were correctly allocated, with 73.2% of the nonrecurrent and 61.5% of the nonrecurrent cases being correctly classified. The specificity and sensitivity were 73.1% and 61.5%, respectively.
Conclusions: Strong immunohistochemical expression of FGFR3, a superficial staining pattern of CK20, and a low proliferative activity define those papillary urothelial neoplasms of low malignant potential that do not recur.
Similar articles
-
FGFR3 mutations and a normal CK20 staining pattern define low-grade noninvasive urothelial bladder tumours.Eur Urol. 2007 Sep;52(3):760-8. doi: 10.1016/j.eururo.2007.01.009. Epub 2007 Jan 12. Eur Urol. 2007. PMID: 17240035
-
Comparison of the WHO/ISUP classification and cytokeratin 20 expression in predicting the behavior of low-grade papillary urothelial tumors. World/Health Organization/Internattional Society of Urologic Pathology.Mod Pathol. 2001 Apr;14(4):267-72. doi: 10.1038/modpathol.3880300. Mod Pathol. 2001. PMID: 11301341
-
Editorial comment on: FGFR3 mutations and a normal CK20 staining pattern define low-grade noninvasive urothelial bladder tumours.Eur Urol. 2007 Sep;52(3):768. doi: 10.1016/j.eururo.2007.01.010. Eur Urol. 2007. PMID: 17240042 No abstract available.
-
Fibroblast growth factor receptor-3 in urothelial tumorigenesis.Urol Oncol. 2013 Apr;31(3):303-11. doi: 10.1016/j.urolonc.2011.12.001. Epub 2012 Jan 30. Urol Oncol. 2013. PMID: 22285006 Review.
-
Reappraisal of the papillary urothelial neoplasm of low malignant potential (PUNLMP).Histopathology. 2020 Oct;77(4):525-535. doi: 10.1111/his.14192. Epub 2020 Sep 13. Histopathology. 2020. PMID: 32562556 Review.
Cited by
-
Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity.Nat Rev Cancer. 2015 Jan;15(1):25-41. doi: 10.1038/nrc3817. Nat Rev Cancer. 2015. PMID: 25533674 Review.
-
FGFR3 mutations, but not FGFR3 expression and FGFR3 copy-number variations, are associated with favourable non-muscle invasive bladder cancer.Virchows Arch. 2014 Aug;465(2):207-13. doi: 10.1007/s00428-014-1596-4. Epub 2014 Jun 1. Virchows Arch. 2014. PMID: 24880661
-
FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder.Cancer Med. 2014 Aug;3(4):835-44. doi: 10.1002/cam4.262. Epub 2014 May 21. Cancer Med. 2014. PMID: 24846059 Free PMC article.
-
Personalized therapy for urothelial cancer: review of the clinical evidence.Clin Investig (Lond). 2011 Apr;1(4):546-555. doi: 10.4155/cli.11.26. Clin Investig (Lond). 2011. PMID: 22754656 Free PMC article.
-
Combined lectin- and immuno-histochemistry (CLIH) for applications in cell biology and cancer diagnosis: Analysis of human urothelial carcinomas.Eur J Histochem. 2020 Jul 1;64(3):3141. doi: 10.4081/ejh.2020.3141. Eur J Histochem. 2020. PMID: 32613817 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials